The continuously activated JAK/STAT pathway in the tumour microenvironment can inhibit the antitumor immune response of immune cells, and IL-6/JAK/STAT signaling has become a popular signal target for tumour therapy [24]. The gene discussed is SOAT1; the disease is neoplasm.